Resources
About Us
Home Report
Store
Asia-Pacific Continuous Bioprocessing Market
Asia-Pacific Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs) - Forecast to 2030
Report ID:MRHC - 104999 Pages: 145 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursThe Asia-Pacific Continuous Bioprocessing Market is expected to grow at a CAGR of 28.9% from 2024 to 2030 to reach $181.1 million by 2030. Continuous manufacturing is an emerging trend spanning various industries. From automotive to paper, businesses are embracing continuous manufacturing to enhance efficiency and bolster profits. The shift from batch to continuous manufacturing is gaining traction in the biopharmaceuticals sector due to the surge in demand for intricate therapies and heightened market competition. Continuous bioprocessing is increasingly being adopted due to its agility, flexibility, efficiency, and robustness. This approach streamlines processes by minimizing steps, utilizing compact facilities and equipment, and enhancing product quality to facilitate real-time release.
The growth of the continuous bioprocessing market in Asia-Pacific is attributed to the gradual adoption of continuous manufacturing, rising manufacturing and research-related outsourcing of biopharmaceuticals, expansions in CDMOs, and initiatives supporting the adoption of biopharmaceuticals. Furthermore, the shift towards bioprocessing 4.0 and the rising adoption of personalized medicines are expected to provide significant market growth opportunities.
However, the limitations of continuous bioprocessing may restrain the growth of this market. Additionally, manufacturers’ hesitation to shift from batch manufacturing to continuous manufacturing poses challenges to the market players.
Click here to: Get Free Sample Pages of this Report
Companies Initiatives for Expanding Biopharma Capacity Drive Asia-Pacific Continuous Bioprocessing Market
The current push of biotech R&D towards establishing a biotherapeutic landscape and improving the regulatory landscape for the development and approval of biosimilars supported companies to expand biopharma capacity:
-
In December 2020, Alvotech (Iceland) and Fuji Pharma, a Japanese pharmaceutical company, extended their partnership to commercialize four biosimilars in Japan.
- In December 2020, RoosterBio, Inc., a South Korean supplier of cellular therapy bioprocess tools, entered into an agreement with Sartorius Korea Biotechto launch RoosterBio’s first international platform with off-the-shelf working cell banks and hMSC bioprocess media products in Asia.
- In October 2020, the company announced raising funding from private equity investors for investments in biologics. In January 2021, Biocon announced an investment of USD 75 million for Biocon Biologics to boost biosimilar development in India.
- Companies like Biocon Ltd. (India) are developing strategies to expand their R&D base in India. In September 2019, Biocon acquired Pfizer Healthcare (U.S.) assets to set up a second R&D facility in India to boost biosimilars development.
- In June 2018, Lupin Limited (India) partnered with Nichi-Iko Pharmaceutical Co., Ltd., to launch biosimilars in the Japanese market.
Support Initiatives for CDMOs Boosts R&D Development in the Asia-Pacific Continuous Bioprocessing Market
The demand for innovative manufacturing methods like continuous processing is rising due to the increasing R&D and bioproduction. For instance,
- In January 2021, Biocon announced an investment of USD 75 million for Biocon Biologics to boost biosimilar development in India.
- In November 2020, South Korea-based Celltrion announced an investment of USD 453 million for building a third manufacturing and R&D site in South Korea.
- In August 2020, one of the leading CDMOs in Japan, Bushu Pharmaceuticals Ltd., announced a major expansion program with an investment of USD 100 million to expand capacity and portfolio.
Key Findings in the Asia-Pacific Continuous Bioprocessing Market Study:
In 2024, the Filtration Systems and Consumables Segment is Expected to Account for the Largest Share of the Asia-Pacific Continuous Bioprocessing Market
In 2024, the filtration systems and consumables segment is estimated to account for the largest share of the Asia-Pacific continuous bioprocessing market. Filtration stands as a preferred purification method in the biopharmaceutical sector. The surge in advanced filtration systems and consumables, such as disposable or single-use systems, combined with the filters' reusability across various bioprocessing steps, contributes to the significant market share of this segment.
In 2024, the Commercial Application Segment is Expected to Account for the Largest Share of the Asia-Pacific Continuous Bioprocessing Market
In 2024, the commercial applications segment is estimated to account for the largest share of the Asia-Pacific continuous bioprocessing market. Growing initiatives supporting the adoption of biopharmaceuticals, rising biopharmaceutical manufacturing outsourcing, growing investments in constructing facilities compatible with continuous bioprocessing for the commercial manufacture of biopharmaceuticals, and accelerated developments in personalized therapies drive the adoption of continuous bioprocessing for commercial application.
In 2024, the Pharmaceutical and Biotechnology Companies Segment is Expected to Account for the Largest Share of Asia-Pacific Continuous Bioprocessing Market
In 2024, the pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the Asia-Pacific continuous bioprocessing market. The large share of this segment is attributed to factors such as the transition of pharma and biopharma manufacturers from batch to continuous processing, regulatory authorities' increasing emphasis on continuous bioprocessing, and the rising investments directed toward the integration of continuous processing technologies.
China to Account for the Largest Market Share in 2024
In 2024, China is estimated to dominate the Asia-Pacific continuous bioprocessing market. Though China has the largest adoption, China’s biopharma sector faces multiple challenges in quality management, including a lack of experience and talent, a rapidly changing regulatory environment, as well as cultural issues in management. These factors are projected to hinder the growth of this market to a certain extent.
Key Players
The report includes a competitive landscape based on the key growth strategies adopted by leading market players in the past four years. The key players profiled in Asia-Pacific continuous bioprocessing market study are 3M Company (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), Solida Biotech GmBH (Germany), Electrolab Biotech Limited (U.K.), Biowest (France), and Bionet (U.S.).
Scope of the Report:
Asia-Pacific Continuous Bioprocessing Market Assessment, by Product
- Filtration Systems and Consumables
- Chromatography Systems and Consumables
- Cell Culture Media, Buffers, and Reagents
- Incubators and Shakers
- Bioreactors
- Centrifuges
- Sterilizers
- Other Instruments and Consumables
Asia-Pacific Continuous Bioprocessing Market Assessment, by Application
- Commercial Applications
- Monoclonal Antibodies (MAB) Production
- Cell and Gene Therapy Production
- Vaccine Manufacturing
- Plasma Fractionation
- Recombinant Protein Production
- Research & Development (R&D)
Asia-Pacific Continuous Bioprocessing Market Assessment, by End User
- Pharmaceutical and Biotechnology Companies
- Contract Development and Manufacturing Organizations (CDMOS) and Contract Research Organizations (CROS)
- Academic and Research Institutes
Asia-Pacific Continuous Bioprocessing Market Assessment, by Country
- China
- India
- Japan
- Singapore
- South Korea
- Australia
- New Zealand
- Indonesia
- Rest of Asia-Pacific (RoE)
Key questions answered in the report:
This report covers the market sizes & forecasts for various products, applications, end user, and geography. It also involves the value analysis of various segments and sub-segments of continuous bioprocessing at the country level.
Asia-Pacific continuous bioprocessing market is projected to reach $181.1 million by 2030, at a CAGR of 28.9% during the forecast period of 2024–2030.
Based on product, in 2024, the filtration systems and consumables segment is estimated to account for the largest share of the Asia-Pacific continuous bioprocessing market.
The growth of this market is attributed to factors such as the gradual adoption of continuous manufacturing, rising manufacturing and research-related outsourcing of biopharmaceuticals, expansions in CDMOs, and initiatives supporting the adoption of biopharmaceuticals. Furthermore, the shift towards bioprocessing 4.0 and the rising adoption of personalized medicines are expected to provide significant market growth opportunities.
The limitations of continuous bioprocessing may restrain the growth of this market.
The key players operating in the Asia-Pacific continuous bioprocessing market are 3M Company (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), Solida Biotech GmBH (Germany), Electrolab Biotech Limited (U.K.), Biowest (France), and Bionet (U.S.).
The market in China is projected to register the highest growth rate during the forecast period and offer significant growth opportunities for the players operating in this market. Rising government initiatives aimed at promoting the adoption of biosimilars, expansion of CDMOs, and government initiatives for biopharma production are key factors driving the market’s growth in China.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Growing Adoption of Continuous Bioprocessing
4.2.1.2. Recent Product Launches and Advances in the Continuous Bioprocessing Space
4.2.1.3. Initiatives Supporting the Adoption of Biopharmaceuticals
4.2.2. Restraints
4.2.2.1. Limitations of Continuous Bioprocessing
4.2.3. Opportunities
4.2.3.1. Shift Towards Bioprocessing 4.0
4.2.3.2. Rising Adoption of Personalized Medicine
4.2.4. Challenges
4.2.4.1. Manufacturers' Reluctance to Shift from Batch Manufacturing to Continuous Manufacturing
4.3. Market Trends
4.4. Parent Market Analysis: Bioprocessing Equipment and Consumables Market
4.5. Porter's Five Forces Analysis
4.5.1. Bargaining Power of Buyers
4.5.2. Bargaining Power of Suppliers
4.5.3. Threat of Substitutes
4.5.4. Threat of New Entrants
4.5.5. Degree of Competition
5. Asia-Pacific Continuous Bioprocessing Market Assessment—by Product
5.1. Overview
5.2. Filtration Systems and Consumables
5.3. Chromatography Systems and Consumables
5.4. Cell Culture Media, Buffers, and Reagents
5.5. Incubators and Shakers
5.6. Bioreactors
5.7. Centrifuges
5.8. Sterilizers
5.9. Other Instruments and Consumables
6. Asia-Pacific Continuous Bioprocessing Market Assessment—by Application
6.1. Overview
6.2. Commercial Applications
6.2.1. Monoclonal Antibodies (mAbs) Production
6.2.2. Cell and Gene Therapy Production
6.2.3. Vaccine Manufacturing
6.2.4. Plasma Fractionation
6.2.5. Recombinant Protein Production
6.3. Research & Development (R&D)
7. Asia-Pacific Continuous Bioprocessing Market Assessment—by End User
7.1. Overview
7.2. Pharmaceutical and Biotechnology Companies
7.3. Contract Development and Manufacturing Organizations (CDMOS) and Contract Research Organizations (CROS)
7.4. Academic and Research Institutes
8. Asia-Pacific Continuous Bioprocessing Market Assessment—by Country
8.1. Overview
8.2. China
8.3. India
8.4. Japan
8.5. Singapore
8.6. South Korea
8.7. Australia
8.8. New Zealand
8.9. Indonesia
8.10. Rest of Asia-Pacific (RoE)
9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share Analysis, by Key Players/ Key Players Market Ranking (2022)
10. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
10.1. 3M Company
10.2. Thermo Fisher Scientific Inc.
10.3. Sartorius AG
10.4. Eppendorf AG
10.5. Pall Corporation
10.6. Cytiva
10.7. Merck KGAA
10.8. Repligen Corporation
10.9. Applikon Biotechnology
10.10. Bionet
10.12. Electrolab Biotech Limited
10.13. Biowest
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
11. Appendix
11.1. Available Customization
11.2. Related Reports
List of Table
Table 1 Asia-Pacific Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 2 Key Companies Offering Filtration Systems and Consumables
Table 3 Filtration Systems and Consumables Market, by Country, 2021-2030 (USD Million)
Table 4 Key Companies Offering Chromatography Systems and Consumables
Table 5 Cell Culture Media, Buffers, and Reagents Market, by Country, 2021-2030 (USD Million)
Table 6 Key Companies Offering Cell Culture Media, Buffers, and Reagents
Table 7 Incubators and Shakers Market, by Country, 2021-2030 (USD Million)
Table 8 Key Companies Offering Incubators and Shakers
Table 9 Bioreactors Market, by Country, 2021-2030 (USD Million)
Table 10 Key Companies Offering Bioreactors
Table 11 Incubators Market, by Country, 2021-2030 (USD Million)
Table 12 Key Companies Offering Incubators
Table 13 Centrifuges Market, by Country, 2021-2030 (USD Million)
Table 14 Key Companies Offering Centrifuges
Table 15 Sterilizers Market, by Country, 2021-2030 (USD Million)
Table 16 Key Companies Offering Sterilizers
Table 17 Other Instruments and Consumables Market, by Country, 2021-2030 (USD Million)
Table 18 Key Companies Offering Other Instruments and Consumables
Table 19 Asia-Pacific Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 20 Asia-Pacific Continuous Bioprocessing Market for Commercial Applications, by Country, 2021-2030 (USD Million)
Table 21 Asia-Pacific Continuous Bioprocessing Market for Monoclonal Antibodies Production, by Country, 2021-2030 (USD Million)
Table 22 Asia-Pacific Continuous Bioprocessing Market for Cell and Gene Therapy Production, by Country, 2021-2030 (USD Million)
Table 23 Asia-Pacific Continuous Bioprocessing Market for Plasma Fractionation, by Country, 2021-2030 (USD Million)
Table 24 Asia-Pacific Continuous Bioprocessing Market for Recombinant Protein Production, by Country, 2021-2030 (USD Million)
Table 25 Asia-Pacific Continuous Bioprocessing Market for R&D Application, by Country, 2021-2030 (USD Million)
Table 26 Asia-Pacific Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 27 Asia-Pacific Continuous Bioprocessing Market for Pharmaceutical and Biotechnology Companies, by Country, 2021-2030 (USD Million)
Table 28 Asia-Pacific Continuous Bioprocessing Market for Contract Development and Manufacturing Organizations and Contract Research Organizations, by Country, 2021-2030 (USD Million)
Table 29 Asia-Pacific Continuous Bioprocessing Market for Academic and Research Institutes, by Country, 2021-2030 (USD Million)
Table 30 Asia-Pacific: Continuous Bioprocessing Market, by Country, 2021-2030 (USD Million)
Table 31 Asia-Pacific: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 32 Asia-Pacific: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 33 Asia-Pacific: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 34 Asia-Pacific: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 35 China: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 36 China: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 37 China: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 38 China: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 39 India: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 40 India: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 41 India: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 42 India: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 43 Japan: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 44 Japan: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 45 Japan: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 46 Japan: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 47 Singapore: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 48 Singapore: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 49 Singapore: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 50 Singapore: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 51 South Korea: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 52 South Korea: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 53 South Korea: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 54 South Korea: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 55 Australia: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 56 Australia: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 57 Australia: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 58 Australia: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 59 New Zealand: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 60 New Zealand: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 61 New Zealand: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 62 New Zealand: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 63 Indonesia: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 64 Indonesia: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 65 Indonesia: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 66 Indonesia: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 75 RoAPAC: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 76 RoAPAC: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 77 RoAPAC: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 78 RoAPAC: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 79 Recent Developments, by Company, 2020-2024
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Asia-Pacific Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Figure 8 Asia-Pacific Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Figure 9 Asia-Pacific Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Figure 10 Asia-Pacific Continuous Bioprocessing Market, by Country, 2024 Vs. 2030 (USD Million)
Figure 11 Impact Analysis: Asia-Pacific Continuous Bioprocessing Market
Figure 12 Asia-Pacific Continuous Bioprocessing Market, by Product, 2024 Vs. 2030 (USD Million)
Figure 13 Asia-Pacific Continuous Bioprocessing Market, by Application, 2024 Vs. 2030 (USD Million)
Figure 14 Asia-Pacific Continuous Bioprocessing Market, by End User, 2024 Vs. 2030 (USD Million)
Figure 15 Asia-Pacific Continuous Bioprocessing Market, by Country, 2021-2030 (USD Million)
Figure 16 Asia-Pacific: Telehealth Market Snapshot
Figure 17 Competitive Dashboard: Asia-Pacific Continuous Bioprocessing Market
Figure 18 3M: Financial Overview (2022)
Figure 19 Thermo Fisher Scientific: Financial Overview (2022)
Figure 20 Sartorius AG: Financial Overview (2022)
Figure 21 Eppendorf AG: Financial Overview (2021)
Figure 22 Danaher Corporation: Financial Overview (2022)
Figure 23 General Electric Company: Financial Overview (2022)
Figure 24 Merck KGaA: Financial Overview (2022)
Figure 25 Getinge AB: Financial Overview (2022)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Asia-Pacific Healthcare IT Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Asia-Pacific Telehealth Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Asia-Pacific Molecular Diagnostics Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Asia-Pacific Livestock Diagnostics Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Europe Continuous Bioprocessing Market - Opportunity Analysis And Industry Forecast (2024-2030)
Published Date: Jul-2024
